RxDoctor Payments Data

Anya Bitterman, MD

Ophthalmology · Oneonta, NYNPI 1760449144

Payments from drug & device makers

$2,006in general payments, 2019–2025

Across 102 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$629
  • Alcon$414
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$317
  • Sun Pharmaceutical Industries Inc.$221
  • Bausch & Lomb Americas Inc.$161
  • Oyster Point Pharma, Inc.$81
  • plus $183 from 6 others

What the payments were for

  • Travel & lodging$1739%
  • Food & beverage$1,78789%
  • Gifts$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,006 in reported general payments places this provider in the 55th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$167,737
Medicare patients
591
Services billed
1,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost296$187,371
RestasisCyclosporine39$68,608
CombiganBrimonidine Tartrate/Timolol61$29,530
XiidraLifitegrast21$28,636
TyrvayaVarenicline Tartrate35$26,764
Cyclosporine36$24,054
RhopressaNetarsudil Mesylate26$20,035
Travoprost49$16,632
Timolol Maleate162$13,112
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol46$12,133
Alphagan PBrimonidine Tartrate26$11,127
Prednisolone Acetate207$9,858
SimbrinzaBrinzolamide/Brimonidine Tart26$8,247
Brinzolamide16$8,227
Latanoprost448$6,654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$629$296,636422 claims
Bausch & Lomb Americas Inc.Xiidra$161$28,63621 claims
Oyster Point Pharma, Inc.Tyrvaya$81$26,76435 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$32$25,05740 claims
AlconSimbrinza$414$8,24726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Oneonta

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →